FANCL Antibody

This product is produced by and distributed for Abnova, a company based in Taiwan.

The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group L. Alternative splicing results in two transcript variants encoding different isoforms. [provided by RefSeq]

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 1 application: WB.

Showing Publication 1 - 1 of 1.

Publication using H00055120-B01P	Applications	Species
Panneerselvam J, Wang H, Zhang J et al. BLM promotes the activation of Fanconi Anemia signaling pathway. Oncotarget. 2016-04-12 [PMID: 27083049] (WB, Human)	WB	Human

Array H00055120-B01P

• FANCL Antibodies
• FANCL Proteins